Trial · NCT06321055
An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States
NCT06321055, Completed, Bayer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States. Trials, record NCT06321055. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06321055
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States
- NCT number
- NCT06321055
- Status
- Completed
- Enrollment
- 136 participants, actual
- Lead sponsor
- Bayer
- Conditions
- Advanced Gastrointestinal Stromal Tumor
- Interventions
- Regorafenib (Stivarga, BAY73-4506)
- First posted
- 2024-03-20
- Last updated
- 2025-05-20
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Duration of Therapy (DOT) on regorafenib | Retrospective analysis from 1 April 2002 to 30 September 2023 | |
| Primary | Time to Next Therapy (TTNT) therapy after regorafenib | Retrospective analysis from 1 April 2002 to 30 September 2023 | |
| Secondary | Number of the guideline-listed medications other than regorafenib | Retrospective analysis from 1 April 2002 to 30 September 2023 | * Imatinib (Gleevec) * Sunitinib (Sutent) * Dasatinib (Sprycel) * Avapritinib (Ayvakit) * Larotrectinib (Vitrakvi) * Entrectinib (Rozlytrek) * Ripretinib (Qinlock) * Dabrafenib (Tafinlar) * Trametinib (Mekinist) * Cabozantinib (Cabometyx) * Nilotinib (Tasigna) * Pazopanib (Votrient) * Sorafenib (Nexavar) * Everolimus in combination with tyrosine kinase inhibitors (Afinitor, Zortress) * Ponatinib (Iclusig) * Binimetinib (Mektovi) |
| Secondary | Descriptive analysis of baseline demographic | Retrospective analysis from 1 April 2002 to 30 September 2023 | |
| Secondary | Descriptive analysis of clinical characteristics | Retrospective analysis from 1 April 2002 to 30 September 2023 | |
| Secondary | Number of patients with evidence of any metastasis on or after the index date during the follow-up period. | Retrospective analysis from 1 April 2002 to 30 September 2023 | |
| Secondary | Number of patients with evidence of surgery on or after the index date during the follow-up period using Current Procedural Terminology (CPT) codes and International Classification of Disease 9/10 Procedure codes (ICD-PC). | Retrospective analysis from 1 April 2002 to 30 September 2023 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06321055
GET https://conductscience.org/api/trials/v1/NCT06321055/registered